Cargando…
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832711/ https://www.ncbi.nlm.nih.gov/pubmed/31601034 http://dx.doi.org/10.3390/jcm8101646 |
_version_ | 1783466232247222272 |
---|---|
author | Ribaldone, Davide Giuseppe Caviglia, Gian Paolo Abdulle, Amina Pellicano, Rinaldo Ditto, Maria Chiara Morino, Mario Fusaro, Enrico Saracco, Giorgio Maria Bugianesi, Elisabetta Astegiano, Marco |
author_facet | Ribaldone, Davide Giuseppe Caviglia, Gian Paolo Abdulle, Amina Pellicano, Rinaldo Ditto, Maria Chiara Morino, Mario Fusaro, Enrico Saracco, Giorgio Maria Bugianesi, Elisabetta Astegiano, Marco |
author_sort | Ribaldone, Davide Giuseppe |
collection | PubMed |
description | The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective study in patients with Crohn’s disease analysing gut microbiota before start of adalimumab therapy (T0) and after six months of therapy (T1). Among the 20 included patients, the phylum Proteobacteria fell from 15.7 ± 3.5% at T0 to 10.3 ± 3.4% at T1 (p = 0.038). Furthermore, the trend in relation to therapeutic success was analysed. Regarding bacterial phyla, Proteobacteria decreased in patients in whom therapeutic success was obtained, passing from a value of 15.8% (± 4.6%) to 6.8 ± 3.1% (p = 0.049), while in non-responder patients, percentages did not change (T0 = 15.6 ± 5.7%, T1 = 16.8 ± 7.6%, p = 0.890). Regarding the Lachnospiraceae family, in patients with normalization of C reactive protein six 6 months of adalimumab therapy, it increased from 16.6 ± 3.1% at T0 to 23.9 ± 2.6% at T1 (p = 0.049). In conclusion, in patients who respond to Adalimumab therapy by decreasing inflammation, there is a trend of intestinal eubiosis being restored. |
format | Online Article Text |
id | pubmed-6832711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68327112019-11-25 Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease Ribaldone, Davide Giuseppe Caviglia, Gian Paolo Abdulle, Amina Pellicano, Rinaldo Ditto, Maria Chiara Morino, Mario Fusaro, Enrico Saracco, Giorgio Maria Bugianesi, Elisabetta Astegiano, Marco J Clin Med Article The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective study in patients with Crohn’s disease analysing gut microbiota before start of adalimumab therapy (T0) and after six months of therapy (T1). Among the 20 included patients, the phylum Proteobacteria fell from 15.7 ± 3.5% at T0 to 10.3 ± 3.4% at T1 (p = 0.038). Furthermore, the trend in relation to therapeutic success was analysed. Regarding bacterial phyla, Proteobacteria decreased in patients in whom therapeutic success was obtained, passing from a value of 15.8% (± 4.6%) to 6.8 ± 3.1% (p = 0.049), while in non-responder patients, percentages did not change (T0 = 15.6 ± 5.7%, T1 = 16.8 ± 7.6%, p = 0.890). Regarding the Lachnospiraceae family, in patients with normalization of C reactive protein six 6 months of adalimumab therapy, it increased from 16.6 ± 3.1% at T0 to 23.9 ± 2.6% at T1 (p = 0.049). In conclusion, in patients who respond to Adalimumab therapy by decreasing inflammation, there is a trend of intestinal eubiosis being restored. MDPI 2019-10-09 /pmc/articles/PMC6832711/ /pubmed/31601034 http://dx.doi.org/10.3390/jcm8101646 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ribaldone, Davide Giuseppe Caviglia, Gian Paolo Abdulle, Amina Pellicano, Rinaldo Ditto, Maria Chiara Morino, Mario Fusaro, Enrico Saracco, Giorgio Maria Bugianesi, Elisabetta Astegiano, Marco Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease |
title | Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease |
title_full | Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease |
title_fullStr | Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease |
title_full_unstemmed | Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease |
title_short | Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease |
title_sort | adalimumab therapy improves intestinal dysbiosis in crohn’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832711/ https://www.ncbi.nlm.nih.gov/pubmed/31601034 http://dx.doi.org/10.3390/jcm8101646 |
work_keys_str_mv | AT ribaldonedavidegiuseppe adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT cavigliagianpaolo adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT abdulleamina adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT pellicanorinaldo adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT dittomariachiara adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT morinomario adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT fusaroenrico adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT saraccogiorgiomaria adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT bugianesielisabetta adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease AT astegianomarco adalimumabtherapyimprovesintestinaldysbiosisincrohnsdisease |